ArticleNeurogenetics2025
Experience in the clinical and genetic diagnosis of a series of Algerian patients with hereditary spastic paraplegias.
Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative diseases that include more than 90 genetic forms. The diagnosis of HSPs is challenging owing to their exceptional clinical and genetic heterogeneity. Using whole exome sequencing (WES), we investigated the genetic and clinical features of 29 patients from 16 Algerian families diagnosed with HSPs. The prevalence of complicated forms was higher than that of pure forms, with interfamilial clinical variability. We identified pathogenic variants in 11 HSPs-causing genes with a diagnostic rate of 81.2%. The diagnosed families mainly presented an autosomal recessive inheritance pattern due to the high frequency of consanguineous marriages in Algeria. Five novel causative variants were identified in the homozygous state: GBA2:c.1351 C > T/p.Arg451Ter in two sisters with the standard SPG46 phenotype; SPG11:c.6530_6534del in three siblings with a complicated HSP phenotype without thin corpus callosum; HPDL:c.862T > C/p.Tyr288His in a patient with complicated HSP; AMFR:c.707 + 1G > A in a patient with a complicated form extending the clinical spectrum of SPG89; and SPAST:c.1076T > C in two sisters with a pure HSP form overlapping with the classical SPG4 phenotype associated with dominant pathogenic variants in the same gene. In one family, reverse phenotyping revealed a case of Kufor-Rakeb syndrome after ATP13A2 variants were identified, showing the importance of dialogue between clinicians and geneticists. This study is the first series of HSPs consisting exclusively of Algerian families. Our findings broaden the clinical and genetic spectrum of HSPs, confirm their high heterogeneity in Algeria, and underline the efficiency of WES as a diagnostic tool for genetically heterogeneous diseases.
Indexed as
Identifiers
40560206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.